Concentra Group Holdings Parent, Inc. (CON) SEC Filings & Earnings Calls

CFO transition introduces execution risk during leadership change, though it is part of a planned succession

“CFO change effective Nov 1, 2026; new CFO is son of outgoing CEO, potential governance perception risk”

Insider selling for diversification may signal lack of confidence, but buyback at discount suggests management sees value.

“Stockholders are entering into the Stock Repurchase Agreement in order to diversify their investment portfolios for financial planning purposes.”

CEO succession introduces transition risk

“Keith Newton to resign as CEO effective Nov 1, 2026; Matt DiCanio appointed.”

Regulatory and reimbursement risk

“State fee schedule changes and regulatory changes could impact revenue.”

Labor cost pressure

“Labor shortages and increased employee turnover could increase operating costs.”

Litigation and Regulatory Risk

“The Company is subject to various legal actions, including a qui tam lawsuit under the California Insurance Fraud Prevention Act, a DOJ investigation into physical therapy billing, and a data breach class action.”

Data Breach Liability

“In February 2024, Concentra sent notices to almost four million patients who may have been impacted by the data breach.” · word for word

Leverage and Debt Service

“As of June 30, 2026, the Company had $1.57 billion in total debt, with a leverage ratio of 2.99x.”

Loss of key executive (CMO) could impact clinical strategy, though consulting agreement mitigates transition risk.

“Dr. John Anderson retiring as EVP and Chief Medical Officer.”

Regulatory changes

“State fee schedule changes undertaken by state workers' compensation boards or commissions and other third-party payors.” · word for word

Labor costs

“Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs.” · word for word

Cybersecurity

“The impacts of any security breaches, cyberattacks, loss of data, or cybersecurity threats or incidents involving our, or our third-party vendors', information technology systems.” · word for word

Net leverage ratio of 3.4x; debt level remains elevated.

“net leverage ratio of approximately 3.4x” · word for word

Key executive departure may cause temporary leadership gap in medical oversight.

“CMO retirement effective Dec 31, 2026; successor not yet named.”

Integration risk from Nova Medical Centers acquisition; leverage at 3.4x.

“One-time capex of $4M for Nova integration; net leverage 3.4x.”

Preliminary results subject to audit adjustments; integration risk from Nova acquisition.

“Preliminary, unaudited results; one-time capex for Nova integration.”

Interest expense increase from debt refinancing

“Interest expense increased to $28.7 million for Q3 2025 from $21.4 million in Q3 2024 due to new term loans and senior notes.”

General and administrative cost pressure from public company costs

“General and administrative expenses increased to 9.2% of revenue from 7.6% due to acquisition costs, separation costs, and new public company infrastructure.”

Integration risk from large acquisitions

“Nova (67 centers) and Pivot Onsite Innovations (240+ clinics) acquired in 2025; integration and transition costs noted.”

High leverage (3.6x net leverage) but targeting reduction.

“Net leverage ratio 3.6x; targeting 3.5x or below by end of 2025 and less than 3.0x by end of 2026.”